IDEAYA Biosciences (IDYA) Total Current Liabilities (2018 - 2026)

IDEAYA Biosciences has disclosed Total Current Liabilities across 9 years of filings, most recently posting $64.8 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $64.8 million, up 27.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.8 million (up 27.5% YoY), and the FY2025 annual result was $58.8 million, up 27.66% from the prior year.
• Total Current Liabilities came in at $64.8 million for Q1 2026 at IDEAYA Biosciences, up from $58.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $64.8 million in Q1 2026 to a low of $24.9 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $40.7 million (2024), against an average of $43.1 million.
• Across the five-year window, Total Current Liabilities plunged 56.38% in 2023 and jumped 103.71% in 2025, its largest moves.
• IDEAYA Biosciences' Total Current Liabilities stood at $31.7 million in 2022, then slipped by 14.56% to $27.1 million in 2023, then surged by 70.0% to $46.1 million in 2024, then advanced by 27.66% to $58.8 million in 2025, then climbed by 10.23% to $64.8 million in 2026.
• The last three Total Current Liabilities figures came in at $64.8 million (Q1 2026), $58.8 million (Q4 2025), and $64.5 million (Q3 2025), per Business Quant data.